Imunon (NASDAQ:IMNN) Announces Earnings Results

Imunon (NASDAQ:IMNN) posted its quarterly earnings data on Tuesday. The company reported ($1.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.24, FiscalAI reports.

Imunon Price Performance

Shares of IMNN stock opened at $2.88 on Tuesday. The firm has a 50-day moving average of $3.20 and a 200-day moving average of $3.93. The company has a market cap of $8.84 million, a P/E ratio of -0.30 and a beta of 2.06. Imunon has a one year low of $2.52 and a one year high of $41.22.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on IMNN shares. reissued a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $255.00.

Institutional Trading of Imunon

An institutional investor recently raised its position in Imunon stock. DRW Securities LLC grew its stake in shares of Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,830 shares of the company’s stock after buying an additional 3,803 shares during the quarter. DRW Securities LLC owned 1.92% of Imunon worth $224,000 at the end of the most recent quarter. 4.47% of the stock is owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.